Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Immunotherapy, including use of checkpoint inhibitors against PD-1, PD-L1, and CTLA-4,
forms the backbone of oncologic management for the majority of non-small cell lung …

Abstract Background BCMA CAR-T is highly effective for relapsed/refractory multiple
myeloma (R/R-MM) and significantly improves the survival of patients. However, the short …

Ferredoxin 1 (FDX1) functions by transferring electrons from NADPH to mitochondrial
cytochrome P450 via the ferredoxin reductase and is the key regulator in copper-dependent …

Intratumoral heterogeneity (ITH) has been linked to decreased efficacy of clinical treatments.
However, although genomic ITH has been characterized in genetic, transcriptomic and …

Background Efficient presentation of mutant peptide fragments by the human leukocyte
antigen class I (HLA-I) genes is necessary for immune-mediated killing of cancer cells …

Purpose As molecules responsible for presenting antigens to T lymphocytes, leukocytes
antigens (HLAs) play a vital role in cancer immunology. This review aims to provide current …

Abstract Machine learning is increasingly used to discover diagnostic and prognostic
biomarkers from high-dimensional molecular data. However, a variety of factors related to …

Progress in the treatment of small cell lung cancer (SCLC) has been modest over the past
decades until the advent of immune checkpoint inhibitors, which have redefined the …

Cancer immunotherapy is an increasingly successful strategy for treating patients with
advanced or conventionally drug-resistant cancers. T cells have been proved to play …